Document:

<PAGE>
                                                                   EXHIBIT 10.80

                              EMPLOYMENT AGREEMENT

           This Employment Agreement dated for reference May 19, 2000.

BETWEEN:

          QLT INC., having an address of 887 Great Northern Way, Vancouver,
          British Columbia, V5T 4T5, Canada,

          ("QLT" or the "COMPANY")

AND:

          DR. ALAIN CURAUDEAU, having an address of 501 Brighton Circle, Devon,
          Pennsylvania 19333, USA,

          ("DR. CURAUDEAU" or the "EMPLOYEE")

WHEREAS:

A.   QLT is a world leader in the development and commercialization of
     proprietary pharmaceutical products for use in photodynamic therapy, an
     emerging field of medicine utilizing light-activated drugs in the treatment
     of disease;

B.   QLT has offered to Dr. Curaudeau, and Dr. Curaudeau has accepted,
     employment with QLT as Vice President of Project Planning and Management;
     and

C.   QLT and Dr. Curaudeau wish to enter into this Agreement to set out the
     terms and conditions of Dr. Curaudeau's employment with QLT.

     NOW THEREFORE in consideration of $10.00, the promises made by each party
to the other as set out in this Agreement and other good and valuable
consideration, the receipt and sufficiency of which the parties acknowledge and
agree, QLT and Dr. Curaudeau agree as follows:

1.       POSITION AND DUTIES

1.1  POSITION - QLT will employ Dr. Curaudeau in the position of Vice President,
     Project Planning and Management, and Dr. Curaudeau agrees to be employed by
     QLT in this position, subject to the terms and conditions of this
     Agreement.

1.2  DUTIES, REPORTING AND EFFORTS - In the performance of his duties as
     Vice-President, Project Planning and Management, Dr. Curaudeau shall, in
     accordance with his Accountability Statement, as may be amended from time
     to time:

     (a)  OVERALL RESPONSIBILITIES - Have overall responsibility for the
          development, implementation and coordination of the Company's project
          planning and management policies, objectives and operations in a
          manner that will ensure achievement of the Company's overall long-term
          strategic objectives.

     (b)  PROJECT PLANNING AND MANAGEMENT - Personally undertake and/or delegate
          all senior administrative responsibilities pertaining to day-to-day
          project planning and management at QLT, in accordance with policies
          established from time to time by the President of the Company (the

                                     Page 1
<PAGE>

                                                                   EXHIBIT 10.80

          "PRESIDENT") and by the Board of Directors of the Company (the
          "BOARD").

     (c)  REPORT - Report, as and when required, to the President.

     (d)  BEST EFFORTS - Use his best efforts, industry and knowledge to improve
          and increase QLT's business and to ensure that QLT is at all times in
          compliance with applicable provincial, state, federal and other
          governing statutes, policies and regulations pertaining to QLT
          business, and in particular, project planning and management at QLT.

     (e)  WORKING DAY - Devote the whole of his working day attention and
          energies to the business and affairs of QLT.

2.       COMPENSATION

2.1  ANNUAL COMPENSATION - In return for his services under this Agreement, the
     Company agrees to pay or otherwise provide the following total annual
     compensation to Dr. Curaudeau:

     (a)  BASE SALARY - A base salary in the amount of US$170,000 in 24 equal
          installments payable semi-monthly in arrears, subject to periodic
          reviews at the discretion of the President and the Board.

     (b)  BENEFIT PLANS - Coverage for Dr. Curaudeau and his eligible dependents
          under any employee benefit plans provided by/through QLT to its
          employees, subject to:

          I.   Each plan's terms for eligibility,
          II.  Dr. Curaudeau taking the necessary steps to ensure effective
               enrollment or registration under each plan, and
          III. Customary deductions of employee contributions for the premiums
               of each plan.

         As at the date of this Agreement, the employee benefit plans provided
         by/through QLT to its employees include life insurance, accidental
         death and dismemberment insurance, dependent life insurance,
         vision-care insurance, health insurance, dental insurance and short and
         long term disability insurance. QLT and Dr. Curaudeau agree that the
         employee benefit plans provided by/through QLT to its employees may
         change from time to time.

     (c)  EXPENSE REIMBURSEMENT - Reimbursement, in accordance with the
          Company's Policy and Procedures Manual (as amended from time to time),
          of all reasonable business related promotion, entertainment and/or
          travel expenses incurred by Dr. Curaudeau, subject to him maintaining
          proper accounts and providing documentation for these expenses upon
          request.

     (d)  VACATION - Four weeks of paid vacation per year, as may be increased
          from time to time in accordance with QLT's standard vacation policy.
          As per the Company's Policy and Procedures Manual (as amended from
          time to time), unless agreed to in writing by the Company:

          I.   All vacation must be taken within one year of the year in which
               it is earned by Dr. Curaudeau, and
          II.  Vacation entitlement shall not be cumulative from year to year.

     (e)  RRSP CONTRIBUTIONS - Provided the conditions set out below have been
          satisfied, in January or February of the year following the year in
          which the income is earned by Dr. Curaudeau (the "INCOME YEAR"), QLT
          shall make a contribution of up to 7% of Dr. Curaudeau's annual base
          salary for the Income Year to Dr. Curaudeau's Registered Retired
          Savings Plan ("RRSP"). The contribution to Dr. Curaudeau's RRSP as set
          out above is subject the following conditions:

                                     Page 2
<PAGE>

                                                                   EXHIBIT 10.80

          I.   The maximum contribution to be made by the Company to Dr.
               Curaudeau's RRSP is 50% of the annual limit for Registered
               Retirement Savings Plans as established by Revenue Canada for the
               Income Year,

          II.  Dr. Curaudeau must have contributed an equal amount into his
               RRSP, and

          III. Dr. Curaudeau is still actively employed by the Company when the
               matching contribution would otherwise be made.

     (f)  CASH INCENTIVE COMPENSATION PLAN - Participation in the Cash Incentive
          Compensation Plan offered by QLT to its senior executives in
          accordance with the terms of such Plan, as amended from time to time
          by the Board. The amount of the payment granted, if any, is at the
          discretion of the Executive Compensation Committee of the Board.

     (g)  STOCK OPTION PLAN - Participation in any stock option plan offered by
          QLT to its employees, in accordance with the terms of the plan in
          effect at the time of the stock option offer(s).

2.2  ADDITIONAL COMPENSATION - In return for his services under this Agreement,
     the Company also agrees to pay or otherwise provide additional special
     compensation to Dr. Curaudeau as more particularly set out in SCHEDULE A to
     this Agreement.

3.       RESIGNATION

3.1  RESIGNATION - Dr. Curaudeau may resign from his employment with QLT by
     giving QLT 60 days prior written notice (the "RESIGNATION NOTICE") of the
     effective date of his resignation. On receiving a Resignation Notice, QLT
     may elect to provide the following payments in lieu of notice to Dr.
     Curaudeau and require him to leave the premises forthwith:

     (a)  BASE SALARY - Base salary owing to Dr. Curaudeau for the 60-day notice
          period.

     (b)  BENEFITS - Except as set out below in this subparagraph 3.1(b), for
          the 60-day notice period, all employee benefit plan coverage enjoyed
          by Dr. Curaudeau and his eligible dependents prior to the date of his
          Resignation Notice. Dr. Curaudeau acknowledges and agrees that pension
          and short and long term disability plans provided through the Company
          will not be continued beyond the last day that Dr. Curaudeau works at
          the Company's premises (the "LAST ACTIVE DAY").

     (c)  EXPENSE REIMBURSEMENT - Reimbursement (in accordance with the
          Company's Policy and Procedures Manual, as amended from time to time)
          of all reasonable business related promotion, entertainment and/or
          travel expenses incurred by Dr. Curaudeau prior to his Last Active
          Day, subject to the expense reimbursement provisions set out in
          subparagraph 2.1(c).

     (d)  VACATION PAY - Payment in respect of accrued but unpaid vacation pay
          owing to Dr. Curaudeau as at the expiry of the 60-day notice period.

     (e)  PRORATED RRSP CONTRIBUTION - A prorated contribution to Dr.
          Curaudeau's RRSP, the pro-ration to be with respect to the portion of
          the current calendar year worked by Dr. Curaudeau, up to and including
          the 60-day notice period, and the contribution to be subject to the
          conditions set out in subparagraph 2.1(e), except condition III.

3.2  OTHERS - In the event of resignation of Dr. Curaudeau as set out in
     paragraph 3.1, the parties agree:

                                     Page 3
<PAGE>

                                                                   EXHIBIT 10.80

     (a)  NO BONUS - Dr. Curaudeau will have no entitlement to participate in
          the Company's Cash Incentive Compensation Plan for the year in which
          he resigns his employment with QLT; and

     (b)  STOCK OPTION PLAN - Dr. Curaudeau's participation in any stock option
          plan offered by QLT to its employees shall be in accordance with the
          terms of the plan in effect at the time of the stock option offer(s)
          to Dr. Curaudeau.

4.       RETIREMENT

4.1  RETIREMENT - Effective the date of retirement (as defined in the Company'
     Policy and Procedures Manual, as amended from time to time) of Dr.
     Curaudeau from active employment with the Company, the parties agree that:

     (a)  THIS AGREEMENT - Subject to the provisions of paragraph 10.6, both
          parties' rights and obligations under this Agreement will terminate
          without further notice or action by either party.

     (b)  STOCK OPTIONS - Dr. Curaudeau's participation in any stock option plan
          offered by QLT to its employees shall be in accordance with the terms
          of the plan in effect at the time of the stock option offer(s) to Dr.
          Curaudeau.

5.       TERMINATION

5.1  TERMINATION FOR CAUSE - QLT reserves the right to terminate Dr. Curaudeau's
     employment at any time for any reason. Should Dr. Curaudeau be terminated
     for cause, he will not be entitled to any advance notice of termination or
     pay in lieu thereof.

5.2  TERMINATION OTHER THAN FOR CAUSE - QLT reserves the right to terminate Dr.
     Curaudeau's employment at any time without reason. However, if QLT
     terminates Dr. Curaudeau's employment for:

     (a)  Any reason other than for cause, or

     (b)  Any reason not covered by a separate Change in Control Letter
          Agreement dated of even date between QLT and Dr. Curaudeau,

     then, except in the case of Dr. Curaudeau becoming completely disabled
     (which is provided for in paragraph 5.8) and subject to the provisions set
     forth below, Dr. Curaudeau shall be entitled to receive notice, pay and/or
     benefits (or any combination of notice, pay and/or benefits) as more
     particularly set out in paragraph 5.3.

5.3  SEVERANCE NOTICE AND PAY - In the event QLT terminates Dr. Curaudeau's
     employment as set out in paragraph 5.2, Dr. Curaudeau shall be entitled to:

     (a)  NOTICE - Advance written notice of termination ("SEVERANCE NOTICE"),
          or pay in lieu thereof ("SEVERANCE Pay"), or any combination of
          Severance Notice and Severance Pay, as more particularly set out
          below:

          I.   A minimum of six months Severance Notice, or Severance Pay in
               lieu thereof, and

          II.  One additional month's Severance Notice for each complete year of
               continuous employment with the Company,

         up to a maximum total of 24 months' Severance Notice, or Severance Pay
         in lieu of Severance

                                     Page 4
<PAGE>

                                                                   EXHIBIT 10.80

          Notice. Dr. Curaudeau acknowledges and agrees that Severance Pay is in
          respect of base salary only and will be made on a bi-weekly or monthly
          basis, at the Company's discretion.

     (b)  BENEFITS - Except as set out below, for 30 days after Dr. Curaudeau's
          Last Active Day, all employee benefit plan coverage enjoyed by Dr.
          Curaudeau and his dependents prior to the date of termination.
          Thereafter, and in lieu of employee benefit plan coverage, Dr.
          Curaudeau shall receive compensation ("BENEFITS COMPENSATION") in the
          amount of 10% of his base salary for the balance of his Severance
          Notice period. Dr. Curaudeau acknowledges and agrees that pension and
          short and long term disability plans provided through the Company will
          not be continued beyond Dr. Curaudeau's Last Active Day.

     (c)  OUT PLACEMENT COUNSELING - In the event QLT terminates Dr. Curaudeau's
          employment as set out in paragraph 5.2, in the year following
          termination, QLT will pay to an out placement counseling service (to
          be agreed to by Dr. Curaudeau and QLT) a maximum of Cdn$5,000 for
          assistance rendered to Dr. Curaudeau in seeking alternative
          employment.

     (d)  OTHER COMPENSATION - In the event QLT terminates Dr. Curaudeau's
          employment as set out in paragraph 5.2, the parties further agree as
          follows:

          I.   The Company will reimburse (in accordance with the Company's
               Policy and Procedures Manual, as amended from time to time) Dr.
               Curaudeau for all reasonable business related promotion,
               entertainment and/or travel expenses incurred by Dr. Curaudeau
               prior to the date of termination, subject to the expense
               reimbursement provisions set out in subparagraph 2.1(c).

          II.  The Company will make a payment to Dr. Curaudeau in respect of
               his accrued but unpaid vacation pay to the date of termination.

          III. The Company will make a prorated contribution to Dr. Curaudeau's
               RRSP, the pro-ration to be with respect to the portion of the
               current calendar year worked by Dr. Curaudeau and the
               contribution to be subject to the conditions set out in
               subparagraph 2.1(e), except condition III.

          IV.  The Company will make a prorated payment to Dr. Curaudeau in
               respect of his entitlement to participate in the Company's Cash
               Incentive Compensation Plan, the pro-ration to be with respect to
               the portion of the current calendar year worked by Dr. Curaudeau
               and the entitlement to be at the maximum level Dr. Curaudeau
               would have otherwise been eligible to receive in the current
               calendar year.

          V.   Dr. Curaudeau's participation in any stock option plan offered by
               QLT to its employees shall be in accordance with the terms of the
               plan in effect at the time of the stock option offer(s) to Dr.
               Curaudeau.

5.4  ACKNOWLEDGEMENT - Dr. Curaudeau acknowledges and agrees that in the event
     QLT terminates Dr. Curaudeau's employment as set out in paragraph 5.2, in
     providing:

     (a)  The Severance Notice or Severance Pay, or any combination thereof;
     (b)  The Benefits Compensation;
     (c)  Out placement counseling service as more particularly set out in
          subparagraph 5.3(c); and
     (d)  The other compensation set out in subparagraph 5.3(d);

     the Company shall have no further obligations, statutory or otherwise, to
     Dr. Curaudeau in respect of this Agreement and Dr. Curaudeau's employment
     under this Agreement.

                                     Page 5
<PAGE>

                                                                   EXHIBIT 10.80

5.5  DUTY TO MITIGATE

     (a)  DUTY TO MITIGATE - Dr. Curaudeau acknowledges and agrees that if his
          employment is terminated as set out in paragraph 5.2, his entitlement
          to Severance Pay, Benefits Compensation and other compensation as set
          out in paragraph 5.3 is subject to his duty to mitigate such payments
          by looking for and accepting suitable alternative employment or
          contract(s) for services.

     (b)  NOTICE - If Dr. Curaudeau obtains new employment or contract(s) for
          services of four weeks or longer, Dr. Curaudeau agrees that he will
          notify QLT of this fact in writing (the "NEW EMPLOYMENT NOTICE")
          within five working days of such an occurrence and in this event the
          following provisions apply:

          I.   Dr. Curaudeau acknowledges and agrees that his entitlement to
               Severance Pay and Benefits Compensation will cease as of the date
               on which his new employment or contract for services commences.

          II.  Within 10 working days of receipt of the New Employment Notice
               from Dr. Curaudeau, QLT agrees that it will pay Dr. Curaudeau a
               lump sum amount equivalent to 50% of the Severance Pay and
               Benefits Compensation as set out in paragraph 5.3 otherwise owing
               to Dr. Curaudeau for the balance of the Severance Notice period.

5.6  FUNDAMENTAL BREACH - Dr. Curaudeau acknowledges and agrees that failure by
     him to provide the New Employment Notice to QLT within five working days as
     set out in paragraph 5.5, or him providing employment or contract(s) for
     services to a company which is in direct competition with QLT in breach of
     paragraph 8.1, will be deemed to be a fundamental breach of this Agreement
     and QLT's obligations to pay Severance Pay, Benefits Compensation and other
     compensation as set out in paragraph 5.3 shall cease immediately.

5.7  NO DUPLICATION - In the event that the Severance Pay provisions of this
     Agreement and the payment provisions of the Change in Control Agreement are
     both applicable, Dr. Curaudeau agrees that he will give written notice to
     the Company with respect to which agreement he wishes to be paid out under
     and that he is not entitled to severance pay under both agreements.

5.8       TERMINATION DUE TO INABILITY TO ACT

     (a)  TERMINATION - QLT may immediately terminate this Agreement by giving
          written notice to Dr. Curaudeau if he becomes completely disabled
          (defined below) to the extent that he cannot perform his duties under
          this Agreement either:

          I.   For a period exceeding six consecutive months, or

          II.  For a period of 180 days (not necessarily consecutive) occurring
               during any period of 365 consecutive days,

         and no other reasonable accommodation can be reached between QLT and
         Dr. Curaudeau. Notwithstanding the foregoing, QLT agrees that it will
         not terminate Dr. Curaudeau pursuant to this provision unless and until
         Dr. Curaudeau has been accepted by the insurer for ongoing long-term
         disability payments or, alternatively, has been ruled definitively
         ineligible for such payments.

     (b)  PAYMENTS - In the event of termination of Dr. Curaudeau's employment
          with the Company pursuant to the provisions of this paragraph 5.8, the
          Company agrees to pay to Dr. Curaudeau Severance Pay and Benefits
          Compensation as set out in paragraph 5.3 and in this situation:

                                     Page 6
<PAGE>

                                                                   EXHIBIT 10.80

          I.   While he is completely disabled Dr. Curaudeau shall have no duty
               to mitigate the payments owing to him by looking for and
               accepting suitable alternative employment or contract(s) for
               service, and

          II.  If Dr. Curaudeau ceases to be completely disabled, then the
               provisions of paragraphs 5.5 (duty to mitigate and notice of new
               employment) and 5.3(c) (out placement counseling) shall apply.

     (c)  DEFINITION - The term "completely disabled" as used in this paragraph
          5.8 shall mean the inability of Dr. Curaudeau to perform the essential
          functions of his position under this Agreement by reason of any
          incapacity, physical or mental, which the Board, based upon medical
          advice or an opinion provided by a licensed physician acceptable to
          the Board, determines to keep Dr. Curaudeau from satisfactorily
          performing any and all essential functions of his position for the
          Company during the foreseeable future.

5.9  DEATH - Except as set out below, effective the date of death (the "DATE OF
     DEATH") of Dr. Curaudeau, this Agreement and both parties' rights and
     obligations under this Agreement shall terminate without further notice or
     action by either party. Within 30 days after the Date of Death (and the
     automatic concurrent termination of this Agreement), the Company shall pay
     the following amounts to Dr. Curaudeau's estate:

     (a)  BASE SALARY - Base salary owing to Dr. Curaudeau up to his Date of
          Death.

     (b)  PAYMENT IN LIEU OF BENEFITS - In lieu of employee benefit coverage for
          his eligible dependents after his Date of Death, a payment in the
          amount of 10% of his annual base salary in effect at his Date of
          Death.

     (c)  EXPENSE REIMBURSEMENT - Reimbursement (in accordance with the
          Company's Policy and Procedures Manual, as amended from time to time)
          of all reasonable business related promotion, entertainment and/or
          travel expenses incurred by Dr. Curaudeau prior to his Date of Death,
          subject to the expense reimbursement provisions set out in
          subparagraph 2.1(c).

     (d)  VACATION PAY - Payment in respect of accrued but unpaid vacation pay
          owing to Dr. Curaudeau as at his Date of Death.

     (e)  RRSP CONTRIBUTION - A prorated contribution to Dr. Curaudeau's RRSP,
          the pro-ration to be with respect to the portion of the current
          calendar year worked by Dr. Curaudeau and the contribution to be
          subject to the conditions set out in subparagraph 2.1(e), except
          condition III.

     (f)  BONUS - A prorated payment to Dr. Curaudeau in respect of his
          entitlement to participate in the Company's Cash Incentive
          Compensation Plan, the pro-ration to be with respect to the portion of
          the current calendar year worked by Dr. Curaudeau and the entitlement
          to be at the maximum level Dr. Curaudeau would have otherwise been
          eligible to receive in the current calendar year.

     After his Date of Death, Dr. Curaudeau's participation and/or entitlement
     under any stock option plan offered by QLT to its employees shall be in
     accordance with the terms of the plan in effect at the time of the stock
     option offer(s) to Dr. Curaudeau.

6.       CONFLICT OF INTEREST

6.1  AVOID CONFLICT OF INTEREST - Except as set out below, during the term of
     his employment with QLT, Dr. Curaudeau agrees to conduct himself at all
     times so as to avoid any real or apparent conflict of interest with the
     activities, policies, operations and interests of QLT. To avoid improper
     appearances, Dr.

                                     Page 7
<PAGE>

                                                                   EXHIBIT 10.80

     Curaudeau agrees that he will not accept any financial compensation of any
     kind, nor any special discount, loan or favour from persons, corporations
     or organizations having dealings or potential dealings with QLT, either as
     a customer or a supplier or a co-venturer. The Company and Dr. Curaudeau
     acknowledge and agree that from time to time the President may consent in
     writing to activities by Dr. Curaudeau which might otherwise appear to be a
     real or apparent conflict of interest.

6.2  NO FINANCIAL ADVANTAGE - During the term of his employment with QLT, Dr.
     Curaudeau agrees that neither he nor any members of his immediate family
     will take financial advantage of or benefit financially from information
     that is obtained in the course of his employment related duties and
     responsibilities unless the information is generally available to the
     public.

6.3  COMPLY WITH POLICIES - During the term of his employment with QLT, Dr.
     Curaudeau agrees to comply with all written policies issued by QLT dealing
     with conflicts of interest.

6.4  BREACH EQUALS CAUSE - Dr. Curaudeau acknowledges and agrees that breach by
     him of the provisions of this Section 6 shall be cause for immediate
     termination by the Company of his employment with the Company.

7.       CONFIDENTIALITY

7.1  INFORMATION HELD IN TRUST - Dr. Curaudeau acknowledges and agrees that all
     business and trade secrets, confidential information and knowledge which
     Dr. Curaudeau acquires during his employment with QLT relating to the
     business and affairs of QLT or to technology, systems, programs, ideas,
     products or services which have been or are being developed or utilized by
     QLT, or in which QLT is or may become interested (collectively,
     "CONFIDENTIAL INFORMATION"), shall for all purposes and at all times, both
     during the term of Dr. Curaudeau's employment with the Company and at all
     times thereafter, be held by Dr. Curaudeau in trust for the exclusive
     benefit of the Company.

7.2  NON DISCLOSURE - Dr. Curaudeau acknowledges and agrees that both during the
     term of his employment with QLT and at all times thereafter, without the
     express or implied consent of QLT, Dr. Curaudeau will not:

     (a)  DISCLOSE - Disclose to any company, firm or person, other than QLT and
          its directors and officers, any of the private affairs of QLT or any
          Confidential Information of QLT; or

     (b)  USE - Use any Confidential Information that he may acquire with
          respect to QLT's affairs for his own purposes or for any purposes,
          other than those of the Company.

7.3      INTELLECTUAL PROPERTY RIGHTS

     (a)  DISCLOSE INVENTIONS - Dr. Curaudeau agrees to promptly disclose to QLT
          any and all ideas, developments, designs, articles, inventions,
          improvements, discoveries, machines, appliances, processes, methods,
          products or the like (collectively, "INVENTIONS") that Dr. Curaudeau
          may invent, conceive, create, design, develop, prepare, author,
          produce or reduce to practice, either solely or jointly with others,
          in the course of his employment with the Company.

     (b)  INVENTIONS ARE QLT PROPERTY - All Inventions and all other work of Dr.
          Curaudeau in the course of his employment with the Company shall at
          all times and for all purposes be the property of QLT for QLT to use,
          alter, vary, adapt and exploit as it shall see fit, and shall be
          acquired or held by Dr. Curaudeau in a fiduciary capacity solely for
          the benefit of QLT.

     (c)  ADDITIONAL REQUIREMENTS - Dr. Curaudeau agrees to:

                                     Page 8
<PAGE>

                                                                   EXHIBIT 10.80

          I.   Treat all information with respect to Inventions as Confidential
               Information.
          II.  Keep complete and accurate records of Inventions, which records
               shall be the property of QLT and copies of which records shall be
               maintained at the premises of QLT.
          III. Execute all assignments and other documents required to assign
               and transfer to QLT (or such other persons as QLT may direct) all
               right, title and interest in and to the Inventions and all other
               work of Dr. Curaudeau in the course of his employment with the
               Company, and all writings, drawings, diagrams, photographs,
               pictures, plans, manuals, software and other materials, goodwill
               and ideas relating thereto, including, but not limited to, all
               rights to acquire in the name of QLT or its nominee(s) patents,
               registration of copyrights, design patents and registrations,
               trade marks and other forms of protection that may be available.
          IV.  Execute all documents and do all acts reasonably requested by QLT
               to give effect to this provision.

7.4  RECORDS - Dr. Curaudeau agrees that all records or copies of records
     concerning QLT's activities, business interests or investigations made or
     received by him during his employment with QLT are and shall remain the
     property of QLT. He further agrees to keep such records or copies in the
     custody of QLT and subject to its control, and to surrender the same at the
     termination of his employment or at any time during his employment at QLT's
     request.

7.5  NO USE OF FORMER EMPLOYER'S MATERIALS - Dr. Curaudeau certifies that he has
     not brought to QLT and will not use while performing his employment duties
     for QLT any materials or documents of any former employer which are not
     generally available to the public, except if the right to use the materials
     or documents has been duly licensed to QLT by the former employer.

8.       POST-EMPLOYMENT RESTRICTIONS

8.1  NON-COMPETE - Dr. Curaudeau agrees that, without the prior written consent
     of QLT, for a period of two years following termination of his employment
     with the Company for any reason (by resignation or otherwise), as measured
     from his Last Active Day, Dr. Curaudeau shall not:

     (a)  PARTICIPATE IN A COMPETITIVE BUSINESS - Directly or indirectly, own,
          manage, operate, join, control or participate in the ownership,
          management, operation or control of, or be a director or an employee
          of, or a consultant to, any business, firm or corporation that, as a
          part of conducting its business, is in any way competitive with QLT
          with respect to:

          I.   The development and/or commercialization and/or marketing of
               light-activated pharmaceutical products for photodynamic therapy
               in the treatment of cancer, opthalmic, auto-immune and
               cardiovascular disease, or
          II.  If the core technology base of the Company diversifies beyond
               photodynamic therapy, the development and/or commercialization
               and/or marketing of pharmaceutical products that are based on a
               significantly similar technology platform and are used in the
               treatment of substantially the same medical indications as
               products which have become a significant component of the
               Company's core business,

          anywhere in Canada, the United States or Europe.

     (b)  SOLICIT ON BEHALF OF A COMPETITIVE BUSINESS - Directly or indirectly
          call upon or solicit any QLT employee or QLT customer or known
          prospective customer of QLT on behalf of any business, firm or
          corporation that, as part of conducting its business, is in any way
          competitive with QLT with respect to:

                                     Page 9
<PAGE>

                                                                   EXHIBIT 10.80

          I.   The development and/or commercialization and/or marketing of
               light-activated pharmaceutical products for photodynamic therapy
               in the treatment of cancer, opthalmic, auto-immune and
               cardiovascular disease, or
          II.  If the core technology base of the Company diversifies beyond
               photodynamic therapy, the development and/or commercialization
               and/or marketing of pharmaceutical products that are based on a
               significantly similar technology platform and are used in the
               treatment of substantially the same medical indications as
               products which have become a significant component of the
               Company's core business,

          anywhere in Canada, the United States or Europe.

     (c)  SOLICIT EMPLOYEES - Directly or indirectly solicit any individual to
          leave QLT's employment for any reason or interfere in any other manner
          with the employment relationship existing between QLT and its current
          or prospective employees.

     (d)  SOLICIT CUSTOMERS - Directly or indirectly induce or attempt to induce
          any customer, supplier, distributor, licensee or other business
          relation of QLT to cease doing business with QLT or in any way
          interfere with the existing business relationship between any such
          customer, supplier, distributor, licensee or other business relation
          and QLT.

8.2  MINORITY SHARE INTERESTS ALLOWED - The parties agree that nothing contained
     in paragraph 8.1 is intended to prohibit Dr. Curaudeau from owning any
     minority interest in any company where stock or shares are traded publicly.

9.       REMEDIES

9.1  IRREPARABLE DAMAGE - Dr. Curaudeau acknowledges and agrees that:

     (a)  BREACH - Any breach of any provision of this Agreement could cause
          irreparable damage to QLT; and

     (b)  CONSEQUENCES OF BREACH - In the event of a breach of any provision of
          this Agreement by him, QLT shall have, in addition to any and all
          other remedies at law or in equity, the right to an injunction,
          specific performance or other equitable relief to prevent any
          violation by him of any of the provisions of this Agreement including,
          without limitation, the provisions of Sections 7 and 8.

9.2  INJUNCTION - In the event of any dispute under Sections 7 and/or 8, Dr.
     Curaudeau agrees that QLT shall be entitled, without showing actual
     damages, to a temporary or permanent injunction restraining his conduct,
     pending a determination of such dispute and that no bond or other security
     shall be required from QLT in connection therewith.

9.3  ADDITIONAL REMEDIES - Dr. Curaudeau acknowledges and agrees that the
     remedies of QLT specified in this Agreement are in addition to, and not in
     substitution for, any other rights and remedies of QLT at law or in equity
     and that all such rights and remedies are cumulative and not alternative or
     exclusive of any other rights or remedies and that QLT may have recourse to
     any one or more of its available rights and remedies as it shall see fit.

10.      GENERAL MATTERS

10.1 TAX WITHHELD - The parties acknowledge and agree that all payments to be
     made by the Company to the Employee under this Agreement will be subject to
     the Company's withholding of applicable withholding taxes.

                                    Page 10
<PAGE>

                                                                   EXHIBIT 10.80

10.2 INDEPENDENT LEGAL ADVICE - Dr. Curaudeau acknowledges that he has obtained
     or had the opportunity to obtain independent legal advice with respect to
     this Agreement and all of its terms and conditions.

10.3 BINDING AGREEMENT - The parties agree that this Agreement shall enure to
     the benefit of and be binding upon each of them and their respective heirs,
     executors, successors and assigns.

10.4 GOVERNING LAW - The parties agree that this Agreement shall be governed by
     and interpreted in accordance with the laws of the Province of British
     Columbia and the laws of Canada applicable to this Agreement. All disputes
     arising under this Agreement will be referred to the Courts of the Province
     of British Columbia, which will have exclusive jurisdiction, unless there
     is mutual agreement to the contrary.

10.5 NOTICE - The parties agree that any notice or other communication required
     to be given under this Agreement shall be in writing and shall be delivered
     personally or by facsimile transmission to the addresses set forth on page
     1 of this Agreement to the attention of the following persons:

     (a)  IF TO THE COMPANY - Attention: President, Fax No. (604) 875-0001,

          WITH A COPY TO:

          Farris, Vaughn, Wills & Murphy
          Barristers & Solicitors
          26th Floor, 700 West Georgia Street
          Vancouver, British Columbia
          V7Y 1B3
          Attention:  R. Hector MacKay-Dunn
          Fax No.:   (604) 661-1730

     (b)  IF TO THE EMPLOYEE - Fax No. ___________;

     or to such other addresses and persons as may from time to time be notified
     in writing by the parties. Any notice delivered personally shall be deemed
     to have been given and received at the time of delivery. Any notice
     delivered by facsimile transmission shall be deemed to have been given and
     received on the next business day following the date of transmission.

10.6     SURVIVAL OF TERMS

     (a)  EMPLOYEE'S OBLIGATIONS - Dr. Curaudeau acknowledges and agrees that
          his representations, warranties, covenants, agreements, obligations
          and liabilities under any and all of Sections 7, 8 and 10 of this
          Agreement shall survive any termination of this Agreement.

     (b)  COMPANY'S OBLIGATIONS - The Company acknowledges and agrees that its
          representations, warranties, covenants, agreements, obligations and
          liabilities under any and all of Sections 3, 4, 5 and 10 of this
          Agreement shall survive any termination of this Agreement.

     (c)  WITHOUT PREJUDICE - Any termination of this Agreement shall be without
          prejudice to any rights and obligations of the parties arising or
          existing up to the effective date of such expiration or termination,
          or any remedies of the parties with respect thereto.

10.7 WAIVER - The parties agree that any waiver of any breach or default under
     this Agreement shall only

                                    Page 11
<PAGE>

                                                                   EXHIBIT 10.80

      be effective if in writing signed by the party against whom the waiver is
      sought to be enforced, and no waiver shall be implied by indulgence, delay
      or other act, omission or conduct. Any waiver shall only apply to the
      specific matter waived and only in the specific instance in which it is
      waived.

10.8  ENTIRE AGREEMENT - The parties agree that the provisions contained in this
      Agreement, Dr. Curaudeau's Change in Control Letter Agreement and any
      Stock Option Agreements between the Company and Dr. Curaudeau constitute
      the entire agreement between QLT and Dr. Curaudeau with respect to the
      subject matters hereof, and supersede all previous communications,
      understandings and agreements (whether verbal or written) between QLT and
      Dr. Curaudeau regarding the subject matters hereof. To the extent that
      there is any conflict between the provisions of this Agreement, Dr.
      Curaudeau's Change in Control Letter Agreement and any Stock Option
      Agreements between the Company and Dr. Curaudeau, the following provisions
      shall apply:

      (a)  CHANGE IN CONTROL - If the conflict is with respect to an event,
           entitlement or obligation in the case of a Change in Control of the
           Company (as defined in the Change in Control Letter Agreement), the
           provisions of the Change in Control Letter Agreement will govern
           (unless the parties otherwise mutually agree).

      (b)  STOCK OPTIONS - If the conflict is with respect to an entitlement or
           obligation with respect to stock options of the Company, the
           provisions of the Stock Option Agreements will govern (unless the
           parties otherwise mutually agree).

      (c)  OTHER - In the event of any other conflict, the provisions of this
           Agreement will govern (unless the parties otherwise mutually agree).

10.9  SEVERABILITY OF PROVISIONS - If any provision of this Agreement as applied
      to either party or to any circumstance is adjudged by a court of competent
      jurisdiction to be void or unenforceable for any reason, the invalidity of
      that provision shall in no way affect (to the maximum extent permissible
      by law):

      (a)  The application of that provision under circumstances different from
           those adjudicated by the court;

      (b)  The application of any other provision of this Agreement; or

      (c)  The enforceability or invalidity of this Agreement as a whole.

      If any provision of this Agreement becomes or is deemed invalid, illegal
      or unenforceable in any jurisdiction by reason of the scope, extent or
      duration of its coverage, then the provision shall be deemed amended to
      the extent necessary to conform to applicable law so as to be valid and
      enforceable or, if the provision cannot be so amended without materially
      altering the intention of the parties, then such provision shall be
      stricken and the remainder of this Agreement will continue in full force
      and effect.

10.10 CAPTIONS - The parties agree that the captions appearing in this Agreement
      have been inserted for reference and as a matter of convenience and in no
      way define, limit or enlarge the scope or meaning of this Agreement or any
      provision.

                                    Page 12
<PAGE>

                                                                   EXHIBIT 10.80

10.11 AMENDMENTS - Any amendment to this Agreement shall only be effective if
      the amendment is in writing and is signed by the Company and Dr.
      Curaudeau.

     IN WITNESS WHEREOF the parties have executed this Agreement as of the day
and year first written above.

QLT INC.

BY:  ____________________________                  _____________________________
     LINDA LUPINI                                  DR. ALAIN CURAUDEAU
     VICE PRESIDENT, HUMAN RESOURCES
     & ADMINISTRATION

                                    Page 13
<PAGE>

                                                                   EXHIBIT 10.80

                                   SCHEDULE A

                             ADDITIONAL COMPENSATION

1.   Additional Compensation as set out in the Company's offer of employment to
     Dr. Curaudeau, a copy of which is attached to this Schedule A.

                                    Page 14Exhibit 10.3

                     AMENDATORY AGREEMENT

     Reference is made to the Restructuring Agreement between
DIONICS, INC. and APPLE BANK FOR SAVINGS dated as of January 31,
1994, as amended by Agreement dated July 11, 2001 between Dionics,
Inc. and D.A.N. Joint Venture, a Limited Partnership (the
"Restructuring Agreement").  Capitalized terms used in this
Agreement shall have the meanings assigned to those terms in the
Restructuring Agreement, unless otherwise defined herein.

     WHEREAS, in connection with the Restructuring Agreement,
Dionics executed and delivered Restructuring Documents to the
Bank;

     WHEREAS, all of the Bank's rights under the Restructuring
Agreement and the Restructuring Documents having been assigned to
D.A.N. Joint Venture, a Limited Partnership ("D.A.N.");

     WHEREAS, Dionics is in default with respect to the payment
of principal and interest under Term Loan A and Term Loan C;

     WHEREAS, D.A.N. has commenced an action against Dionics in
the Supreme Court of the State of New York, County of New York,
index no. 02/604364 (the "Action");

     WHEREAS, the parties have agreed to resolve such issues as
hereinafter set forth and discontinue the Action, without
prejudice;

     NOW, THEREFORE, the parties hereby covenant and agree as
follows:

     1.    D.A.N. represents and warrants that it is the
lawful ultimate assignee of the Bank with respect to all of the
Bank's rights under the Restructuring Agreement and the
Restructuring Documents and with respect to all of the outstanding
indebtedness of Dionics as reflected therein.  None of such
interests has been transferred or otherwise encumbered and no
other party has any rights with respect thereto.

     2.   The parties hereby acknowledge and agree that as
of December 31, 2002, the principal balance owing on Term Loan A
is in the amount of $90,063.82 (the "Term Loan A Principal
Balance") and the principal balance owing on Term Loan C is in the
amount of $53,146.35 (the "Term Loan C Principal Balance").  The
Term Loan A Principal Balance shall be repaid, together with
interest thereon at the rate of 10.25% per annum (the "Revised
Interest Rate"), in 15 equal consecutive monthly payments of
$6,422.69 each, commencing January 1, 2003, and ending on March
1, 2004 (the "Maturity Date") consisting of principal and interest
calculated at the Revised Interest Rate.  The Term Loan C
Principal Balance shall be repaid, together with interest thereon
at  the Revised Interest Rate, in 15 equal consecutive monthly
payments of $3,790.00 each, commencing January 1, 2003, and ending
on the Maturity Date consisting of principal and interest
calculated at the Revised Interest Rate.

     3.   The parties acknowledge and agree that the total
past due interest as of December 31, 2002, on Term Loan A is in
the aggregate amount of $3,421.17 (the "Loan A Aggregate Past Due
Interest").  All payments on Term Loan A will be applied first to
any accrued and unpaid interest, then to principal, in accordance
with D.A.N.'s accounting system.

     4.   The parties acknowledge and agree that the total
past due interest as of December 31, 2002, on Term Loan C is in
the aggregate amount of $2,018.82 (the "Loan C Aggregate Past Due
Interest").  All payments on Term Loan C will be applied first to
any accrued and unpaid interest, then to principal, in accordance
with D.A.N.'s accounting system.

     5.   Upon execution of this Agreement, D.A.N. agrees to
immediately (i) withdraw the Motion for Summary Judgment pending
in the Action and scheduled to be heard on January 16, 2003
and (ii) discontinue the Action in its entirety without prejudice.

     6.   Dionics agrees to pay D.A.N. the reasonable
attorneys fees incurred pursuant to the Restructuring Agreement
dated January 31, 1994, which shall be paid by Dionics on or
before January 15, 2003, subject to receipt by Dionics of an
itemized bill from D.A.N.'s counsel.

     7.   This Agreement may be executed in counterparts,
each of which shall be deemed an original but all of which
together shall constitute one and the same instrument.  This
Agreement shall be binding and become effective when each party
hereto shall have received by telecopier a counterpart hereof
signed by the other party hereto.

     8.   Except as specifically amended herein, the
Restructuring Agreement and the Restructuring Documents shall
remain in full force and effect and are hereby ratified and
confirmed.

     9.   Each of the parties hereto represents, warrants and
covenants that it has had ample opportunity to consider entering
into this Agreement and has had an opportunity to consult with
counsel regarding this Agreement prior to executing the same.

     10.  Upon maturity of this agreement, Dionics will be
responsible for any unpaid principal, interest and attorney fees
then due.

     IN WITNESS WHEREOF, the parties hereto have executed and
delivered the foregoing Agreement on this 2nd day of January, 2003.

               D.A.N. Joint Venture,
               a Limiteded Partnership,
               by its General Partner,
               Cadle Company of Ohio Inc.

               By:     /s/ Jon D. Gluckner
               Name:   Jon D. Glucker
               Title:  Assistant Vive President

               Dionics, Inc.

               By:     /s/ Bernard Kravitz
               Name:     Bernard Kravitz
               Title:    President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}]]